Vanguard Group
OMGA

Vanguard Group’s Omega Therapeutics, Inc. Common Stock OMGA Stock Holding History

Vanguard Group’s Portfolio OMGA Stock Details OMGA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,097,106
Closed -$818K – 4326
2024
Q4 		$818K Sell
1,097,106
-17,625
-2% -$17.6K ﹤0.01% 3824
2024
Q3 		$1.36M Hold
1,114,731
– – ﹤0.01% 3679
2024
Q2 		$2.31M Sell
1,114,731
-165,194
-13% -$389K ﹤0.01% 3510
2024
Q1 		$4.67M Sell
1,279,925
-229,263
-15% -$879K ﹤0.01% 3324
2023
Q4 		$4.54M Buy
1,509,188
+23,553
+2% +$47.7K ﹤0.01% 3328
2023
Q3 		$3.19M Buy
1,485,635
+1,413
+0.1% +$5.65K ﹤0.01% 3431
2023
Q2 		$8.31M Buy
1,484,222
+85,302
+6% +$667K ﹤0.01% 3049
2023
Q1 		$8.44M Buy
1,398,920
+423,300
+43% +$2.95M ﹤0.01% 3027
2022
Q4 		$5.57M Sell
975,620
-15,529
-2% -$87.2K ﹤0.01% 3256
2022
Q3 		$5.37M Buy
991,149
+241,526
+32% +$1.22M ﹤0.01% 3289
2022
Q2 		$2.85M Sell
749,623
-102,681
-12% -$382K ﹤0.01% 3652
2022
Q1 		$5.32M Buy
852,304
+509,492
+149% +$5.2M ﹤0.01% 3499
2021
Q4 		$3.88M Buy
342,812
+10,604
+3% +$202K ﹤0.01% 3748
2021
Q3 		$6.26M Buy
+332,208
New +$6.37M ﹤0.01% 3513

Other funds holding OMGA

Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
PS
Principal Securities Des Moines, Iowa $6.82B AUM 17.15% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Vanguard Group's OMGA Position: Q1 2025 in Review

Vanguard Group sold out of Omega Therapeutics, Inc. Common Stock (OMGA) in Q1 2025, closing a stake of 1,097,106 shares — an estimated $818K sold.

Vanguard Group first reported a position in OMGA in Q3 2021 and held it in 14 quarters. The position peaked at $8.44M in Q1 2023. 4 funds tracked by Wall St. Rank hold OMGA as of Q1 2025.

  • Vanguard Group reported no remaining Omega Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Vanguard Group sold 1,097,106 Omega Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $818K.
  • Vanguard Group first reported a position in Omega Therapeutics, Inc. Common Stock in Q3 2021 and held it in 14 quarters.
  • Vanguard Group's Omega Therapeutics, Inc. Common Stock position peaked at $8.44M in Q1 2023.
  • 4 funds tracked by Wall St. Rank held Omega Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Vanguard Group's 13F filing for Q1 2025, filed 9 May 2025.